When a nerve impulse arrives at a noradrenaline nerve terminal, noradrenaline is released from synaptic vesicles into the synaptic cleft. Noradrenaline molecules bind to their receptors on the post-synaptic membrane and the nerve impulse is propagated or inhibited, depending on the specific receptor. Noradrenaline molecules are then released from their receptors and taken back into the nerve terminal via the noradrenaline re-uptake transporter. Noradrenaline is degraded by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).1,2

file_download Download in HQ

Related content

description Article
Substance Use Disorders and Behavioral Addictions with Special Consideration of Psychiatric Comorbidity

Individuals with addictive disorders frequently have medical and (underlying) psychiatric comorbid conditions and high disease burden

26.02.2025 Substance Use Disorders
image Image There are many aspects of Parkinson’s disease (PD) that can intensify the caregiver burden (e.g., impaired movement, sleep disorders, pain, cognitive impairment, etc.).
Perceived caregiver burden as Parkinson’s disease advances

There are many aspects of Parkinson’s disease (PD) that can intensify the caregiver burden

22.02.2025 Parkinson’s Disease
image Image An analysis published in 2020, and including indirect costs, estimated that the total annual economic cost of PD will exceed $79 billion by 2037 in the US alone.
The predicted burden of Parkinson’s disease in the USA up to 2037

An analysis published in 2020, and including indirect costs, estimated that the total annual economic cost of PD will exceed $79 billion by 2037 in the US alone

22.02.2025 Parkinson’s Disease